Agios is a biopharmaceutical company that is fueled by connections. Building bonds and cultivating relationships are at the heart of our ability to discover, develop, and deliver therapies for people with rare diseases. Agios is advancing a clinical pipeline of investigational medicines with programs in α- and β thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia